{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:31:19Z","timestamp":1792801879174,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"28","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite aggressive multimodal therapy, including cytotoxic chemotherapy, surgery, and radiation, the prognosis for patients with Ewing sarcoma remains poor, particularly for those with metastatic or relapsed disease. Combining agents that increase DNA replication stress with ATR-CHK1-WEE1 pathway inhibitors, which disrupt the DNA damage response and cell cycle checkpoints, is a promising strategy under clinical investigation in Ewing sarcoma and other cancers. However, the mechanisms by which these drug combinations selectively kill cancer cells under replication stress remain incompletely understood and are often attributed, without strong supporting evidence in many tumor types, to forced mitotic entry. In this study, we show that inhibition of the ATR-CHK1-WEE1 pathway in S-phase-arrested Ewing sarcoma cells triggers rapid apoptosis within 2\u20134\u2009h, without widespread mitotic entry. This apoptotic response is driven by the activation of cyclin-dependent kinase 1 (CDK1) and is caspase-dependent. We further show that dual targeting of DNA replication and ATR-CHK1-WEE1 signaling in Ewing sarcoma tumors suppresses protein synthesis, and inhibition of protein synthesis prevents cell cycle progression and premature mitotic entry\u2014providing a mechanistic explanation for why aberrant CDK1 activation does not drive mitosis in this context. Moreover, while apoptosis is induced rapidly following drug treatment, the suppression of protein synthesis is prolonged and persists beyond drug removal, suggesting distinct early and late mechanisms of drug-induced toxicity. Collectively, these findings define a unique CDK1- and caspase-dependent apoptotic pathway in response to replication stress and offer new insights into the molecular basis of this therapeutic vulnerability in Ewing sarcoma.<\/jats:p>","DOI":"10.1038\/s41388-026-03845-2","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:00:43Z","timestamp":1781128843000},"page":"2823-2839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma"],"prefix":"10.1038","volume":"45","author":[{"given":"Stacia L.","family":"Koppenhafer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary V.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian T.","family":"Mhindu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A. O.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1830-4371","authenticated-orcid":false,"given":"David J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"3845_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1158\/1541-7786.MCR-20-0651","volume":"19","author":"JC Martin","year":"2021","unstructured":"Martin JC, Hoegel TJ, Lynch ML, Woloszynska A, Melendy T, Ohm JE. Exploiting replication stress as a novel therapeutic intervention. Mol Cancer Res. 2021;19:192\u2013206.","journal-title":"Mol Cancer Res"},{"key":"3845_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"Gaillard H, Garc\u00eda-Muse T, Aguilera A. Replication stress and cancer. Nat Rev Cancer. 2015;15:276\u201389.","journal-title":"Nat Rev Cancer"},{"key":"3845_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1101\/gad.345454.120","volume":"35","author":"XA Su","year":"2021","unstructured":"Su XA, Ma D, Parsons JV, Replogle JM, Amatruda JF, Whittaker CA, et al. RAD21 is a driver of chromosome 8 gain in Ewing sarcoma to mitigate replication stress. Genes Dev. 2021;35:556\u201372.","journal-title":"Genes Dev"},{"key":"3845_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep33926","volume":"6","author":"CL Osgood","year":"2016","unstructured":"Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, et al. 18F-FLT positron emission tomography (PET) is a pharmacodynamic marker for EWS-FLI1 activity and Ewing sarcoma. Sci Rep. 2016;6:33926.","journal-title":"Sci Rep"},{"key":"3845_CR5","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1158\/1078-0432.CCR-14-2112","volume":"21","author":"S-W Tang","year":"2015","unstructured":"Tang S-W, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, et al. SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma. Clin Cancer Res. 2015;21:4184\u201393.","journal-title":"Clin Cancer Res"},{"key":"3845_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","volume":"201","author":"J Murai","year":"2019","unstructured":"Murai J, Thomas A, Miettinen M, Pommier Y. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol Ther. 2019;201:94\u2013102.","journal-title":"Pharmacol Ther"},{"key":"3845_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09659-z","volume":"10","author":"G Mondal","year":"2019","unstructured":"Mondal G, Stevers M, Goode B, Ashworth A, Solomon DA. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers. Nat Commun. 2019;10:1686.","journal-title":"Nat Commun"},{"key":"3845_CR8","doi-asserted-by":"publisher","first-page":"e1004475","DOI":"10.1371\/journal.pgen.1004475","volume":"10","author":"AS Brohl","year":"2014","unstructured":"Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014;10:e1004475.","journal-title":"PLoS Genet"},{"key":"3845_CR9","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/2159-8290.CD-13-1037","volume":"4","author":"BD Crompton","year":"2014","unstructured":"Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014;4:1326\u201341.","journal-title":"Cancer Discov"},{"key":"3845_CR10","doi-asserted-by":"publisher","first-page":"e1465014","DOI":"10.1080\/23723556.2018.1465014","volume":"5","author":"A Gorthi","year":"2018","unstructured":"Gorthi A, Bishop AJR. Ewing sarcoma fusion oncogene: at the crossroads of transcription and DNA damage response. Mol Cell Oncol. 2018;5:e1465014.","journal-title":"Mol Cell Oncol"},{"key":"3845_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature25748","volume":"555","author":"A Gorthi","year":"2018","unstructured":"Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, et al. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature. 2018;555:387\u201391.","journal-title":"Nature"},{"key":"3845_CR12","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1158\/0008-5472.CAN-25-2166","volume":"86","author":"DE Gracilla","year":"2026","unstructured":"Gracilla DE, Menon S, Breese MR, Lin YP, Dela Cruz FS, Feinberg TY, et al. FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. Cancer Res. 2026;86:2660\u201377.","journal-title":"Cancer Res"},{"key":"3845_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1541-7786.MCR-19-0585","volume":"18","author":"SL Koppenhafer","year":"2020","unstructured":"Koppenhafer SL, Goss KL, Terry WW, Gordon DJ. Inhibition of the ATR-CHK1 pathway in Ewing sarcoma cells causes DNA damage and apoptosis via the CDK2-mediated degradation of RRM2. Mol Cancer Res. 2020;18:91\u2013104.","journal-title":"Mol Cancer Res"},{"key":"3845_CR14","doi-asserted-by":"publisher","first-page":"87016","DOI":"10.18632\/oncotarget.18776","volume":"8","author":"KL Goss","year":"2017","unstructured":"Goss KL, Koppenhafer SL, Harmoney KM, Terry WW, Gordon DJ. Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine. Oncotarget. 2017;8:87016\u201332.","journal-title":"Oncotarget"},{"key":"3845_CR15","doi-asserted-by":"publisher","first-page":"63003","DOI":"10.18632\/oncotarget.11416","volume":"7","author":"KL Goss","year":"2016","unstructured":"Goss KL, Gordon DJ. Gene expression signature-based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Oncotarget. 2016;7:63003\u201319.","journal-title":"Oncotarget"},{"key":"3845_CR16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/2767-9764.CRC-23-0268","volume":"3","author":"EE Croushore","year":"2023","unstructured":"Croushore EE, Koppenhafer SL, Goss KL, Geary EL, Gordon DJ. Activator protein-1 (AP-1) signaling inhibits the growth of Ewing sarcoma cells in response to DNA replication stress. Cancer Res Commun. 2023;3:1580\u201393.","journal-title":"Cancer Res Commun"},{"key":"3845_CR17","doi-asserted-by":"publisher","first-page":"8605","DOI":"10.1007\/s00432-023-04804-0","volume":"149","author":"M-J Sturm","year":"2023","unstructured":"Sturm M-J, Henao-Restrepo JA, Becker S, Proquitt\u00e9 H, Beck JF, Sonnemann J. Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells. J Cancer Res Clin Oncol. 2023;149:8605\u201317.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3845_CR18","doi-asserted-by":"publisher","first-page":"58759","DOI":"10.18632\/oncotarget.11643","volume":"7","author":"M Nieto-Soler","year":"2016","unstructured":"Nieto-Soler M, Morgado-Palacin I, Lafarga V, Lecona E, Murga M, Callen E, et al. Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget. 2016;7:58759\u201367.","journal-title":"Oncotarget"},{"key":"3845_CR19","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1158\/1078-0432.CCR-23-3063","volume":"30","author":"J Jess","year":"2024","unstructured":"Jess J, Sorensen KM, Boguslawski EA, Stout MC, Madaj ZB, Caiello BP, et al. Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma. Clin Cancer Res. 2024;30:3533\u201348.","journal-title":"Clin Cancer Res"},{"key":"3845_CR20","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/2767-9764.CRC-25-0058","volume":"5","author":"SL Koppenhafer","year":"2025","unstructured":"Koppenhafer SL, Geary EL, Thomas MV, Croushore EE, Zimmerman JAO, Gedminas JM, et al. Histone deacetylase inhibitors target DNA replication regulators and replication stress in Ewing sarcoma cells. Cancer Res Commun. 2025;5:1034\u201348.","journal-title":"Cancer Res Commun"},{"key":"3845_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-031-00793-4_5","volume":"99","author":"MJC Long","year":"2022","unstructured":"Long MJC, Ly P, Aye Y. Still no rest for the reductases: ribonucleotide reductase (RNR) structure and function: an update. Subcell Biochem. 2022;99:155\u201397.","journal-title":"Subcell Biochem"},{"key":"3845_CR22","doi-asserted-by":"crossref","unstructured":"Rundle S, Bradbury A, Drew Y, Curtin NJ. Targeting the ATR-CHK1 axis in cancer therapy. Cancers. 2017.","DOI":"10.3390\/cancers9050041"},{"key":"3845_CR23","doi-asserted-by":"crossref","unstructured":"Orecki L, Andrs M, Korabecny J. Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. Cancers (Basel). 2021;13:795..","DOI":"10.3390\/cancers13040795"},{"key":"3845_CR24","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-18-0260","volume":"17","author":"SL Koppenhafer","year":"2018","unstructured":"Koppenhafer SL, Goss KL, Terry WW, Gordon DJ. mTORC1\/2 and protein translation regulate levels of CHK1 and the sensitivity to CHK1 inhibitors in Ewing sarcoma cells. Mol Cancer Ther. 2018;17:2676\u201388.","journal-title":"Mol Cancer Ther"},{"key":"3845_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13691-2","volume":"25","author":"J Ziener","year":"2025","unstructured":"Ziener J, Henao-Restrepo JA, Leonhardi J, Sturm M-J, Becker S, Morales-Prieto DM, et al. Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing\u2019s sarcoma cells. BMC Cancer. 2025;25:277.","journal-title":"BMC Cancer"},{"key":"3845_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1158\/2767-9764.CRC-22-0130","volume":"2","author":"JC Martin","year":"2022","unstructured":"Martin JC, Sims JR, Gupta A, Bakin AV, Ohm JE. WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe. Cancer Res Commun. 2022;2:471\u201382.","journal-title":"Cancer Res Commun"},{"key":"3845_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01393-9","volume":"20","author":"S Ohmura","year":"2021","unstructured":"Ohmura S, Marchetto A, Orth MF, Li J, Jabar S, Ranft A, et al. Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021;20:97.","journal-title":"Mol Cancer"},{"key":"3845_CR28","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","volume":"2","author":"M Aarts","year":"2012","unstructured":"Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012;2:524\u201339.","journal-title":"Cancer Discov"},{"key":"3845_CR29","doi-asserted-by":"publisher","first-page":"108808","DOI":"10.1016\/j.celrep.2021.108808","volume":"34","author":"TB Branigan","year":"2021","unstructured":"Branigan TB, Kozono D, Schade AE, Deraska P, Rivas HG, Sambel L, et al. MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity. Cell Rep. 2021;34:108808.","journal-title":"Cell Rep"},{"key":"3845_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.231","volume":"5","author":"P Zuazua-Villar","year":"2014","unstructured":"Zuazua-Villar P, Rodriguez R, Gagou ME, Eyers PA, Meuth M. DNA replication stress in CHK1-depleted tumour cells triggers premature (S-phase) mitosis through inappropriate activation of Aurora kinase B. Cell Death Dis. 2014;5:e1253.","journal-title":"Cell Death Dis"},{"key":"3845_CR31","doi-asserted-by":"publisher","first-page":"6835","DOI":"10.1158\/0008-5472.CAN-04-2246","volume":"65","author":"MA Morgan","year":"2005","unstructured":"Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res. 2005;65:6835\u201342.","journal-title":"Cancer Res"},{"key":"3845_CR32","doi-asserted-by":"publisher","first-page":"21074","DOI":"10.18632\/oncotarget.4020","volume":"6","author":"JPY Mak","year":"2015","unstructured":"Mak JPY, Man WY, Chow JPH, Ma HT, Poon RYC. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells. Oncotarget. 2015;6:21074\u201384.","journal-title":"Oncotarget"},{"key":"3845_CR33","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.4161\/cc.5.17.3184","volume":"5","author":"MA Morgan","year":"2006","unstructured":"Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle. 2006;5:1983\u20138.","journal-title":"Cell Cycle"},{"key":"3845_CR34","doi-asserted-by":"publisher","first-page":"39246","DOI":"10.1074\/jbc.M505009200","volume":"280","author":"H Niida","year":"2005","unstructured":"Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N, Nakanishi M. Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem. 2005;280:39246\u201352.","journal-title":"J Biol Chem"},{"key":"3845_CR35","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41388-020-01552-0","volume":"40","author":"KL Goss","year":"2021","unstructured":"Goss KL, Koppenhafer SL, Waters T, Terry WW, Wen K-K, Wu M, et al. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. Oncogene. 2021;40:564\u201377.","journal-title":"Oncogene"},{"key":"3845_CR36","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1038\/s41388-022-02310-0","volume":"41","author":"SL Koppenhafer","year":"2022","unstructured":"Koppenhafer SL, Goss KL, Voigt E, Croushore E, Terry WW, Ostergaard J, et al. Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in Ewing sarcoma. Oncogene. 2022;41:2873\u201384.","journal-title":"Oncogene"},{"key":"3845_CR37","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1080\/15384101.2018.1547001","volume":"17","author":"GD Grant","year":"2018","unstructured":"Grant GD, Kedziora KM, Limas JC, Cook JG, Purvis JE. Accurate delineation of cell cycle phase transitions in living cells with PIP-FUCCI. Cell Cycle. 2018;17:2496\u2013516.","journal-title":"Cell Cycle"},{"key":"3845_CR38","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0960-9822(98)70156-3","volume":"8","author":"T Kanda","year":"1998","unstructured":"Kanda T, Sullivan KF, Wahl GM. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol. 1998;8:377\u201385.","journal-title":"Curr Biol"},{"key":"3845_CR39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nmeth.1314","volume":"6","author":"EK Schmidt","year":"2009","unstructured":"Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009;6:275\u20137.","journal-title":"Nat Methods"},{"key":"3845_CR40","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1096\/fj.10-168799","volume":"25","author":"CA Goodman","year":"2011","unstructured":"Goodman CA, Mabrey DM, Frey JW, Miu MH, Schmidt EK, Pierre P, et al. Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. FASEB J. 2011;25:1028\u201339.","journal-title":"FASEB J"},{"key":"3845_CR41","doi-asserted-by":"publisher","first-page":"e1700492","DOI":"10.1002\/biot.201700492","volume":"13","author":"F Nagelreiter","year":"2018","unstructured":"Nagelreiter F, Coats MT, Klanert G, Gludovacz E, Borth N, Grillari J, et al. OPP labeling enables total protein synthesis quantification in CHO production cell lines at the single-cell level. Biotechnol J. 2018;13:e1700492.","journal-title":"Biotechnol J"},{"key":"3845_CR42","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1073\/pnas.1707514115","volume":"115","author":"CM Forester","year":"2018","unstructured":"Forester CM, Zhao Q, Phillips NJ, Urisman A, Chalkley RJ, Oses-Prieto JA, et al. Revealing nascent proteomics in signaling pathways and cell differentiation. Proc Natl Acad Sci USA 2018;115:2353\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3845_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","volume":"22","author":"AABA da Costa","year":"2023","unstructured":"da Costa AABA, Chowdhury D, Shapiro GI, D\u2019Andrea AD, Konstantinopoulos PA. Targeting replication stress in cancer therapy. Nat Rev Drug Discov. 2023;22:38\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"3845_CR44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/nar\/gkr697","volume":"40","author":"CS S\u00f8rensen","year":"2012","unstructured":"S\u00f8rensen CS, Sylju\u00e5sen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2012;40:477\u201386.","journal-title":"Nucleic Acids Res"},{"key":"3845_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1385\/1-59259-973-7:073","volume":"314","author":"X Huang","year":"2006","unstructured":"Huang X, Darzynkiewicz Z. Cytometric assessment of histone H2AX phosphorylation: a reporter of DNA damage. Methods Mol Biol. 2006;314:73\u201380.","journal-title":"Methods Mol Biol"},{"key":"3845_CR46","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1158\/0008-5472.CAN-18-3631","volume":"79","author":"T Ubhi","year":"2019","unstructured":"Ubhi T, Brown GW. Exploiting DNA replication stress for cancer treatment. Cancer Res. 2019;79:1730\u20139.","journal-title":"Cancer Res"},{"key":"3845_CR47","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1073\/pnas.0712168105","volume":"105","author":"A Salic","year":"2008","unstructured":"Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA 2008;105:2415\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3845_CR48","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s10495-022-01735-y","volume":"27","author":"S Kari","year":"2022","unstructured":"Kari S, Subramanian K, Altomonte IA, Murugesan A, Yli-Harja O, Kandhavelu M. Programmed cell death detection methods: a systematic review and a categorical comparison. Apoptosis. 2022;27:482\u2013508.","journal-title":"Apoptosis"},{"key":"3845_CR49","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/liv.12570","volume":"35","author":"FJ Barreyro","year":"2015","unstructured":"Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953\u201366.","journal-title":"Liver Int"},{"key":"3845_CR50","doi-asserted-by":"publisher","first-page":"eaan4368.","DOI":"10.1126\/science.aan4368","volume":"358","author":"S Klaeger","year":"2017","unstructured":"Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P-A, et al. The target landscape of clinical kinase drugs. Science. 2017;358:eaan4368.","journal-title":"Science"},{"key":"3845_CR51","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-14-1037","volume":"14","author":"C King","year":"2015","unstructured":"King C, Diaz HB, McNeely S, Barnard D, Dempsey J, Blosser W, et al. LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms. Mol Cancer Ther. 2015;14:2004\u201313.","journal-title":"Mol Cancer Ther"},{"key":"3845_CR52","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/cbin.10259","volume":"38","author":"L Zhou","year":"2014","unstructured":"Zhou L, Cai X, Han X, Xu N, Chang DC. CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2\/Bax family proteins during treatment with microtubule-interfering agents. Cell Biol Int. 2014;38:737\u201346.","journal-title":"Cell Biol Int"},{"key":"3845_CR53","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/sj.cdd.4401130","volume":"9","author":"M Castedo","year":"2002","unstructured":"Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ. 2002;9:1287\u201393.","journal-title":"Cell Death Differ"},{"key":"3845_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03607-8","volume":"24","author":"G Kim","year":"2024","unstructured":"Kim G, Jang S-K, Ahn SH, Kim S, Park CS, Seong M-K, et al. Proapoptotic role of CDK1 in overcoming paclitaxel resistance in ovarian cancer cells in response to combined treatment with paclitaxel and duloxetine. Cancer Cell Int. 2024;24:409.","journal-title":"Cancer Cell Int"},{"key":"3845_CR55","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1073\/pnas.0600447103","volume":"103","author":"LT Vassilev","year":"2006","unstructured":"Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA 2006;103:10660\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3845_CR56","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1021\/jm0102046","volume":"44","author":"JS Lazo","year":"2001","unstructured":"Lazo JS, Aslan DC, Southwick EC, Cooley KA, Ducruet AP, Joo B, et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem. 2001;44:4042\u20139.","journal-title":"J Med Chem"},{"key":"3845_CR57","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","volume":"8","author":"H Hirai","year":"2009","unstructured":"Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009;8:2992\u20133000.","journal-title":"Mol Cancer Ther"},{"key":"3845_CR58","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","volume":"604","author":"D Gallo","year":"2022","unstructured":"Gallo D, Young JTF, Fourtounis J, Martino G, \u00c1lvarez-Quil\u00f3n A, Bernier C, et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022;604:749\u201356.","journal-title":"Nature"},{"key":"3845_CR59","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1080\/15384101.2019.1598725","volume":"18","author":"AB Alber","year":"2019","unstructured":"Alber AB, Suter DM. Dynamics of protein synthesis and degradation through the cell cycle. Cell Cycle. 2019;18:784\u201394.","journal-title":"Cell Cycle"},{"key":"3845_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/1747-1028-6-5","volume":"6","author":"W-Y Tarn","year":"2011","unstructured":"Tarn W-Y, Lai M-C. Translational control of cyclins. Cell Div. 2011;6:5.","journal-title":"Cell Div"},{"key":"3845_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10:11.","journal-title":"Signal Transduct Target Ther"},{"key":"3845_CR62","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41420-022-00877-x","volume":"8","author":"JC Martin","year":"2022","unstructured":"Martin JC, Sims JR, Gupta A, Hagoel TJ, Gao L, Lynch ML, et al. CDC7 kinase (DDK) inhibition disrupts DNA replication leading to mitotic catastrophe in Ewing sarcoma. Cell Death Discov. 2022;8:85.","journal-title":"Cell Death Discov"},{"key":"3845_CR63","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","volume":"28","author":"SX Pfister","year":"2015","unstructured":"Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell. 2015;28:557\u201368.","journal-title":"Cancer Cell"},{"key":"3845_CR64","doi-asserted-by":"publisher","first-page":"5726","DOI":"10.1128\/MCB.00731-10","volume":"30","author":"Y Matthess","year":"2010","unstructured":"Matthess Y, Raab M, Sanhaji M, Lavrik IN, Strebhardt K. Cdk1\/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol. 2010;30:5726\u201340.","journal-title":"Mol Cell Biol"},{"key":"3845_CR65","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1242\/jcs.192310","volume":"130","author":"Y Hou","year":"2017","unstructured":"Hou Y, Allan LA, Clarke PR. Phosphorylation of XIAP by CDK1-cyclin-B1 controls mitotic cell death. J Cell Sci. 2017;130:502\u201311.","journal-title":"J Cell Sci"},{"key":"3845_CR66","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1038\/emboj.2010.112","volume":"29","author":"ME Harley","year":"2010","unstructured":"Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 2010;29:2407\u201320.","journal-title":"EMBO J"},{"key":"3845_CR67","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s10495-013-0928-1","volume":"19","author":"CR Han","year":"2014","unstructured":"Han CR, Jun DY, Lee JY, Kim YH. Prometaphase arrest-dependent phosphorylation of Bcl-2 and Bim reduces the association of Bcl-2 with Bak or Bim, provoking Bak activation and mitochondrial apoptosis in nocodazole-treated Jurkat T cells. Apoptosis. 2014;19:224\u201340.","journal-title":"Apoptosis"},{"key":"3845_CR68","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1038\/emboj.2009.253","volume":"28","author":"JL Andersen","year":"2009","unstructured":"Andersen JL, Johnson CE, Freel CD, Parrish AB, Day JL, Buchakjian MR, et al. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. EMBO J. 2009;28:3216\u201327.","journal-title":"EMBO J"},{"key":"3845_CR69","first-page":"5897","volume":"62","author":"K Harada","year":"2002","unstructured":"Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002;62:5897\u2013901.","journal-title":"Cancer Res"},{"key":"3845_CR70","first-page":"2704","volume":"61","author":"N Mitsiades","year":"2001","unstructured":"Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing\u2019s sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res. 2001;61:2704\u201312.","journal-title":"Cancer Res"},{"key":"3845_CR71","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/1078-0432.CCR-06-1457","volume":"13","author":"ASK de Hooge","year":"2007","unstructured":"de Hooge ASK, Berghuis D, Santos SJ, Mooiman E, Romeo S, Kummer JA, et al. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin Cancer Res. 2007;13:206\u201314.","journal-title":"Clin Cancer Res"},{"key":"3845_CR72","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/bjc.2015.298","volume":"113","author":"Z Kang","year":"2015","unstructured":"Kang Z, Goldstein SD, Yu Y, Meltzer PS, Loeb DM, Cao L. Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing\u2019s sarcoma. Br J Cancer. 2015;113:894\u2013901.","journal-title":"Br J Cancer"},{"key":"3845_CR73","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1038\/sj.onc.1204750","volume":"20","author":"S Fulda","year":"2001","unstructured":"Fulda S, K\u00fcfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001;20:5865\u201377.","journal-title":"Oncogene"},{"key":"3845_CR74","doi-asserted-by":"publisher","first-page":"107901","DOI":"10.1016\/j.celrep.2020.107901","volume":"32","author":"S Lockhead","year":"2020","unstructured":"Lockhead S, Moskaleva A, Kamenz J, Chen Y, Kang M, Reddy AR, et al. The apparent requirement for protein synthesis during G2 phase is due to checkpoint activation. Cell Rep. 2020;32:107901.","journal-title":"Cell Rep"},{"key":"3845_CR75","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1021\/acsptsci.1c00150","volume":"4","author":"JW Hinds","year":"2021","unstructured":"Hinds JW, Ditano JP, Eastman A. Inhibition of protein synthesis induced by CHK1 inhibitors discriminates sensitive from resistant cancer cells. ACS Pharm Transl Sci. 2021;4:1449\u201361.","journal-title":"ACS Pharm Transl Sci"},{"key":"3845_CR76","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1021\/acsptsci.0c00201","volume":"4","author":"JP Ditano","year":"2021","unstructured":"Ditano JP, Eastman A. Comparative activity and off-target effects in cells of the CHK1 inhibitors MK-8776, SRA737, and LY2606368. ACS Pharm Transl Sci. 2021;4:730\u201343.","journal-title":"ACS Pharm Transl Sci"},{"key":"3845_CR77","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.molcel.2025.01.008","volume":"85","author":"A Ogawa","year":"2025","unstructured":"Ogawa A, Izumikawa K, Tate S, Isoyama S, Mori M, Fujiwara K, et al. SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis. Mol Cell. 2025;85:894\u2013912.e10.","journal-title":"Mol Cell"},{"key":"3845_CR78","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1126\/science.adh7950","volume":"384","author":"NJ Boon","year":"2024","unstructured":"Boon NJ, Oliveira RA, K\u00f6rner P-R, Kochavi A, Mertens S, Malka Y, et al. DNA damage induces p53-independent apoptosis through ribosome stalling. Science. 2024;384:785\u201392.","journal-title":"Science"},{"key":"3845_CR79","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1158\/1535-7163.MCT-21-0089","volume":"20","author":"J Gartrell","year":"2021","unstructured":"Gartrell J, Mellado-Largarde M, Clay MR, Bahrami A, Sahr NA, Sykes A, et al. SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to replicative stress caused By DNA-damaging agents. Mol Cancer Ther. 2021;20:2151\u201365.","journal-title":"Mol Cancer Ther"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03845-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:02:46Z","timestamp":1783375366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03845-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":79,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2026,7,28]]}},"alternative-id":["3845"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03845-2","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}